NEW YORK (GenomeWeb) – MDxHealth today announced the signing of agreements that increase the number of covered lives with access to its ConfirmMDx for Prostate Cancer test to more than 152 million in the US.

The company signed separate agreements with Ancillary Care Services, a subsidiary of American CareSource Holdings, and with Consilium, a division of preferred provider organization Devon Health Services. The agreements permit the adjudication of claims and payment for ConfirmMDx for insured patients, MDxHealth said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.